

The rules governing medicinal products
in the European Union

Volume 2B

Notice to Applicants

Medicinal products for human use

Presentation and content
of the dossier

1998 Edition



EUROPEAN COMMISSION
Directorate General III – Industry
Pharmaceuticals and cosmetics

THE RULES GOVERNING MEDICINAL PRODUCTS IN THE EUROPEAN UNION

Volume 1 Pharmaceutical legislation
Medicinal products for human use

Volume 2 Notice to applicants
Medicinal products for human use

Volume 3 Guidelines
Medicinal products for human use

Volume 4 Good manufacturing practices
Medicinal products for human and veterinary use

Volume 5 Pharmaceutical legislation
Veterinary medicinal products

Volume 6 Notice to applicants
Veterinary medicinal products

Volume 7 Guidelines
Veterinary medicinal products

Volume 8 Maximum residue limits
Veterinary medicinal products

Volume 9 Pharmacovigilance
Medicinal products for human use and veterinary medicinal products

FOREWORD

This Notice to Applicants (NTA) has been prepared by the European Commission, in consultation with the competent authorities of the Member States and the European Agency for the Evaluation of Medicinal Products. This Notice has no legal force and does not necessarily represent the final views of the Commission. In case of doubt, therefore, reference should be made to the appropriate Community Directives. It is important when reading this text to appreciate that the legal requirements of the Directives and the Regulation must be met and that this Notice presents the harmonised views of the Member States on how those requirements may be met.

The Notice to Applicants (Volume 2 in the series “The Rules governing Medicinal Products in the European Union”) was first published in 1986. A revised and completed version, the second edition, was issued in January '89. Since then, the procedures for applications for a marketing authorisation have been amended in order to introduce the centralised and mutual recognition procedures. The resulting size of NTA has meant that it has been divided into parts

- Volume 2A dealing with procedures for marketing authorisation;
- Volume 2B dealing with the presentation and content of the application dossier.

Volume 2B is concerned with the structure and content of the application dossier (Parts I, II, III, IV). It provides guidance for the compilation of dossiers for applications for marketing authorization, and is applicable for the centralised procedure and national procedures, including mutual recognition. The requirements for the content of the application dossier are set out in Directive 75/318/EEC as amended, i.e. “the particulars and documents accompanying an application for marketing authorization pursuant to Article 4 of Council Directive 65/65/EEC shall be presented in four parts, in accordance with the requirements set out in the Annex to that directive, taking account of the guidance published by the Commission in *The rules governing medicinal products in the European Union, Volume 2: Notice to applicants for marketing authorisations for medicinal products for human use*”.

The content of the dossier (Volume 2B) has not been changed since 1989 with the exception of additions in order to take account of those medicinal products brought within the scope of Directive 65/65/EEC as a result of the ‘extension’ directives i.e. radiopharmaceuticals, medicinal products derived from human blood and plasma and homeopathics; as well as occasional clarifications as requested by the pharmaceutical industry. In order to provide regulatory authorities and the pharmaceutical industry with a ‘single source’ document, the current text of the 1989 edition of the Notice to Applicants has been re-presented, with those additions and clarifications already (consulted upon and) adopted duly incorporated.

Therefore, the text of the 1989 edition is replaced by this volume.

In order to facilitate the preparation of the dossier, particularly the tabular presentations, this volume is also available on a diskette.

OVERVIEW

INTRODUCTION	i
PART I – SUMMARY	1
PART II – CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION	175
PART III – TOXICO-PHARMACOLOGICAL DOCUMENTATION	205
PART IV – CLINICAL DOCUMENTATION	207
NOTES	209

TABLE OF CONTENTS

Foreword	iii
INTRODUCTION	xix
PART I SUMMARY OF THE DOSSIER	1
PART I A SUMMARY OF THE DOSSIER	1
Administrative data	1
Fees, declaration and signature	1
Type of application	1
1. This application concerns:	2
2. The application is in accordance with the following legal base:	2
3. This is an application for:	3
Marketing authorization particulars	9
PART I B 1 SUMMARY OF PRODUCT CHARACTERISTICS	17
Summary of the product characteristics: list of headings	18
1. Trade name of the medicinal product	19
2. Qualitative and quantitative composition	19
3. Pharmaceutical form	19
4. Clinical particulars	19
5. Pharmacological properties	21
6. Pharmaceutical particulars	22
7. Marketing authorization holder	23
8. Marketing authorization number	23
9. Date of first authorization/renewal of authorization	23
10. Date of (partial) revision of the text	23
PART I B 2 PROPOSAL FOR PACKAGING, LABELLING & PACKAGE LEAFLET	23
PART I B 3 SPCS ALREADY APPROVED IN THE MEMBER STATES	23
PART I C EXPERT REPORTS	24
A. Introduction	24
B. Presentation of the expert report	24
C. Expert reports for abridged applications	26
PART I C 1 EXPERT REPORT ON THE CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION	28
A. Introduction	28
— Product profile	28
— Expert report	28
— Appendices to the expert report	28
B. Expert report on the chemical, pharmaceutical and biological documentation	29
C. General aspects	30

D.	Critical assessment	31
	1. Composition of the product:	31
	2. Development pharmaceuticals:	31
	3. Stereoisomerism:	31
	4. Method of preparation:	32
	5. Process validation:	32
	6. Control of pharmacopoeial active substance(s) :	32
	7. Control of non-pharmacopoeial active substance(s):	32
	8. Excipients:	33
	9. Packaging material (immediate packaging):	33
	10. Control tests on intermediate products:	33
	11. Control tests on the finished product:	33
	12. Stability of the active substance(s):	33
	13. Stability of the finished product:	33
	14. Other information:	33
	15. Reference list:	34
	16. Information on the qualifications and experience of the pharmaceutical expert:	34
E.	Tabular formats	35
F.	Tabular formats for radiopharmaceutical products	36
PART I C 2	EXPERT REPORT ON THE TOXICO-PHARMACOLOGICAL (PRE-CLINICAL) DOCUMENTATION	79
A.	Introduction	79
	— Product profile	79
	— Expert report	79
	— Appendices to the expert report	79
B.	Expert report on the toxico-pharmacological documentation	80
C.	General aspects	81
D.	Critical assessment	82
	1. Pharmacodynamics	82
	2. Pharmacokinetics	82
	3. Toxicity	82
	4. Conclusions	83
	5. Reference list	83
	6. Information on the toxico-pharmacological (pre-clinical) experts	83
E.	Tabular formats	84
PART I C 3	EXPERT REPORT ON THE CLINICAL DOCUMENTATION	159
A.	Introduction	159
	— Product profile	159
	— Expert report	159
	— Appendice to the expert report	159
B.	Expert report on the clinical documentation	160
C.	General aspects	161
D.	Critical assessment	162
	1. Clinical pharmacology (Part IV A)	162
	2. Pharmacodynamics	162
	3. Pharmacokinetics	162
	4. Clinical trials (PART IV B)	164

5.	Post marketing experience	166
6.	Other information	167
7.	Conclusion	167
8.	Reference list	167
9.	Information on the clinical expert	167
E.	Tabular formats	168
PART II CONCERNING CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR CHEMICAL ACTIVE SUBSTANCE(S)		175
PART II A: COMPOSITION		175
1.	Composition of the medicinal product	175
2.	Container (brief description)	175
3.	Clinical trial formula(e)	175
4.	Development pharmaceuticals	175
PART II B: METHOD OF PREPARATION		176
1.	Manufacturing formula (including details of batch size)	176
2.	Manufacturing process	176
3.	Validation of the process	176
PART II C: CONTROL OF STARTING MATERIALS		176
1.	Active substance(s)	176
2.	Excipient(s)	177
3.	Packaging material (immediate packaging)	177
PART II D: CONTROL TESTS ON INTERMEDIATE PRODUCTS (IF NECESSARY)		178
PART II E: CONTROL TESTS ON THE FINISHED PRODUCT		178
1.	Specifications and routine tests	178
2.	Scientific data	178
PART II F: STABILITY		178
1.	Stability tests on active substance(s)	178
2.	Stability tests on the finished product	179
PART II H: DATA RELATED TO THE ENVIRONMENTAL RISK ASSESSMENT FOR PRODUCTS CONTAINING, OR CONSISTING OF GENETICALLY MODIFIED ORGANISMS (GMOS)		180
PART II Q: OTHER INFORMATION		180
PART II CONCERNING CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR RADIOPHARMACEUTICAL PRODUCTS		181
PART II A: COMPOSITION		181
1.	Composition of the medicinal product	181
2.	Container (brief description)	181

■ Table of contents

3.	Clinical trial formula(e)	181
4.	Development pharmaceuticals	182
PART II B:	METHOD OF PREPARATION	182
1.	Manufacturing formula (including details of batch size)	182
2.	Manufacturing process	182
3.	Validation of the process	182
PART II C:	CONTROL OF STARTING MATERIALS	182
1.	Active substance(s)	182
2.	Excipient(s)	184
3.	Packaging material (immediate packaging)	184
PART II D:	CONTROL TESTS ON INTERMEDIATE PRODUCTS (IF NECESSARY)	184
PART II E:	CONTROL TESTS ON THE FINISHED PRODUCT	184
1.	Specifications and routine tests	184
2.	Scientific data	184
PART II F:	STABILITY	185
1.	Stability tests on active substance(s)	185
2.	Stability tests on the finished product	185
PART II G:	BIOAVAILABILITY/BIOEQUIVALENCE	185
PART II H:	DATA RELATED TO THE ENVIRONMENTAL RISK ASSESSMENT FOR PRODUCTS CONTAINING, OR CONSISTING OF GENETICALLY MODIFIED ORGANISMS (GMOS)	186
PART II Q:	OTHER INFORMATION	186
PART II CONCERNING CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR BIOLOGICAL MEDICINAL PRODUCTS		187
PART II A:	COMPOSITION	187
1.	Composition of the medicinal product	187
2.	Container (brief description)	187
3.	Clinical trial formula(e)	187
4.	Development pharmaceuticals	187
PART II B:	METHOD OF PREPARATION	188
1.	Manufacturing formula	188
2.	Manufacturing process	188
3.	Validation of the process	188
PART II C:	PRODUCTION AND CONTROL OF STARTING MATERIALS	188
1.	Active substance(s)	188
2.	Excipient(s)	188

3.	Packaging material (immediate packaging)	191
PART II D:	CONTROL TESTS ON INTERMEDIATE PRODUCTS	191
PART II E:	CONTROL TESTS ON THE FINISHED PRODUCT	191
1.	Specifications and routine tests	191
2.	Scientific data	192
PART II F:	STABILITY	192
1.	Stability tests on active substance(s)	192
2.	Stability tests on the finished product	192
PART II G:	BIOAVAILABILITY/BIOEQUIVALENCE	192
PART II H:	DATA RELATED TO THE ENVIRONMENTAL RISK ASSESSMENT FOR PRODUCTS CONTAINING, OR CONSISTING OF GENETICALLY MODIFIED ORGANISMS (GMOS)	194
Part IIIH-1.		194
Part IIIH-2.		194
Part IIIH-3.		194
Part IIIH-4.		194
Part IIIH-5.		194
Part IIIH-6.		194
PART II Q:	OTHER INFORMATION	194
PART II V:	VIROLOGICAL DOCUMENTATION	194
1.	Brief presentation of the finished product	195
2.	Starting materials and biological reagents used in production	195
3.	Production process	196
4.	Validation studies on the process	196
5.	Virological control tests during the production process	197
6.	Pharmacovigilance (surveillance of the viral safety)	197
7.	Expert report	197
PART II CONCERNING	CHEMICAL, PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR VEGETABLE MEDICINAL PRODUCTS	199
PART II A:	COMPOSITION	199
1.	Composition of the medicinal product	199
2.	Container (brief description)	199
3.	Clinical trial formula(e)	199
4.	Development pharmaceuticals	199
PART II B:	METHOD OF PREPARATION	200
1.	Manufacturing formula (including details of batch size)	200
2.	Manufacturing process	200
3.	Validation of the process	200

■ Table of contents

PART II C:	CONTROL OF STARTING MATERIALS	200
1.	Active substance(s)	200
2.	Excipients	200
3.	Packaging material (immediate packaging)	200
PART II D:	CONTROL TESTS ON INTERMEDIATE PRODUCTS (IF NECESSARY)	203
PART II E:	CONTROL TESTS ON THE FINISHED PRODUCT	203
1.	Specifications and routine tests	203
2.	Scientific data	203
PART II F:	STABILITY	204
1.	Stability tests on active substance(s)	204
2.	Stability tests on the finished product	204
PART II G:	BIOAVAILABILITY/BIOEQUIVALENCE	204
PART II H:	DATA RELATED TO THE ENVIRONMENTAL RISK ASSESSMENT FOR PRODUCTS CONTAINING, OR CONSISTING OF GENETICALLY MODIFIED ORGANISMS (GMOS)	204
PART II Q:	OTHER INFORMATION	204
PART III	TOXICO-PHARMACOLOGICAL DOCUMENTATION	205
PART III A:	TOXICITY	205
PART III B:	REPRODUCTIVE FUNCTION (FERTILITY AND GENERAL REPRODUCTIVE PERFORMANCE)	205
PART III C:	EMBRYO-FOETAL AND PERINATAL TOXICITY	205
PART III D:	MUTAGENIC POTENTIAL	205
PART III E:	CARCINOGENIC POTENTIAL	205
PART III F:	PHARMACODYNAMICS	206
PART III G:	PHARMACOKINETICS	206
PART III H:	LOCAL TOLERANCE (WHERE APPROPRIATE)	206
PART III Q :	OTHER INFORMATION	206
PART III R:	ENVIRONMENTAL RISK ASSESSMENT / ECOTOXICITY	206
PART IV	CLINICAL DOCUMENTATION	207

PART IV A: CLINICAL PHARMACOLOGY	207
1. Pharmacodynamics	207
2. Pharmacokinetics	207
PART IV B: CLINICAL EXPERIENCE	208
1. Clinical trials	208
2. Post-marketing experience (if available)	208
3. Published and unpublished experience (other than 1.)	208
PART IV Q: OTHER INFORMATION	208
NOTES	209

INTRODUCTION

1. PRESENTATION OF THE APPLICATION

The Community application dossier, which should be submitted in either a Community or national procedure (i.e. to competent authorities of the Member States and the European Agency for the Evaluation of Medicinal Products), consists of administrative information and the necessary demonstration of quality, safety and efficacy of the product.

This is presented in four Parts (I, II, III, IV).

Part I – Summary of the dossier

Part II – Chemical/pharmaceutical/biological tests

Part III – Toxicopharmacological tests

Part IV – Clinical documentation.

2. PART 1

Part I is divided into 3 sub-sections:

- **Part IA** consists of the administrative data, packaging, samples, manufacturing and marketing authorisations applied for or obtained elsewhere (previously in Part V of the dossier). A harmonised format for Part IA has been agreed.
- **Part IB** consists of the proposed Summary of Product Characteristics (SPC) and package leaflet, in accordance with Article 4a of Directive 65/65/EEC. The sequence given in the guideline has been accepted by the competent authorities of all Member States, and places the clinical data in a more prominent location.
- **Part IC** consists of the Expert Reports and their Annexes.

Parts IA, IB and IC are always required. Part IB must be in the language(s) of the Member State concerned or in all Community languages for centralised applications.

2.1 Experts Reports in the application dossier

Directive 75/319/EEC as amended requires that the particulars and documents submitted in the application dossier are drawn up and signed by experts, with the necessary technical or professional qualifications. The chemical/pharmaceutical/biological, toxicopharmacological and clinical parts of the dossier should each include an Expert Report. The Expert Reports, their tabular formats and written summaries are placed in Part IC of the dossier.

It is important to emphasise that well prepared Expert Reports greatly to facilitate the task of the competent authority in evaluating the dossier and contribute towards the speedy processing of applications. For these reasons particular care should be taken in the preparation of Expert Reports, following the guidance on the preparation of Expert Reports given in this volume.

Where relevant Community guidelines on the conduct of tests, studies and trials on a medicinal product exist, these should be taken into consideration when Expert Reports are prepared. Any deviation from guidelines should be discussed and justified. In particular, the

experts should give a justification for the statements in the proposed summary of product characteristics (SPC), taking into account the submitted data and the SPC guideline and also considering the need for bioavailability studies with reference to the guideline on bioavailability and bioequivalence in Volume III of the Rules governing medicinal products in the European Union.

2.2 Presentation of the Expert Report

Experience has shown that many applications, particularly for new active substances, have included a written summary as well as the tabulations to the Expert Reports.

Competent authorities have generally found these to be helpful. However, it is considered important to clarify the purpose of the appendices to the Expert Reports in order to avoid duplication and overlap.

It is important to avoid duplication, repetition between the Expert Report and the written summary. Equally, experience has shown that a good tabular presentation with a short written summary is an effective method of communication. Therefore, where tabular formats suffice, it is not necessary to duplicate the message in writing.

— Quality

For the quality part of the dossier, the tabular formats are considered to fulfil the function of a written summary (except in the case of biotechnology medicinal products and medicinal product which contain or consists of genetically modified organisms where a written summary of not more than 30 pages would be helpful).

The assessment report prepared by the competent authority on Part II of the dossier consists of three parts:

- annotations on the tabulated formats of the Expert Report;
- annotations on the critical part of the Expert Report (including a critical appraisal section of the Active Ingredient Manufacturers restricted part (of a DMF file);
- a critical evaluation by the assessor of key features of the dossier.

When the assessment report is to serve as the basis of mutual recognition, the applicant will be invited to provide a revised and updated version of the critical discussion and the tabulated formats of the Expert Report, based on an updated Part II of the dossier. These revisions would take into account all of the points raised during the assessment. It is these revised and updated documents which will form the basis of the (updated) assessment report referred to in Article 9.3 of Directive 75/319/EEC as amended.

— Safety

For the toxicological section of the dossier, the tabular formats are considered to fulfil the function of a written summary.

For the pharmacological section of Part III of the dossier, a written summary could be useful. Normally, the written summary would not be more than 10 pages.

It is considered helpful to have an overview table which would precede a written summary. This overview table would form part of the assessment report.

The assessment report would include a critical analysis of the Part III Expert Report, tabular formats, overview table, written summary, in the light of knowledge of the detail of the submitted dossier of study reports.

— Efficacy

A written summary can be helpful for large, complex clinical documentation. In order to aid clarity, an overview table of clinical studies should precede the written summary.

This overview table would form part of the assessment report.

The written summary should be factual, complete (i.e. covering all studies) and concise.

Normally, it would not be longer than 30 pages. However, in cases of complex dossiers, with multiple indications and/or large numbers of patients evaluable for safety and efficacy, a larger summary (up to 100 pages) could be necessary.

3. TECHNICAL DOCUMENTATION

Parts II, III, and IV of the application dossier consist of the chemical, pharmaceutical and biological documentation; the toxicological and pharmacological documentation; and the clinical documentation respectively.

In Part IV, Clinical Documentation, case report forms are always required to be available.

Although it is not necessary to include these in the submission, applicants should be prepared to supply them normally within 48 hours of any request by the competent authority and in any event within 7 calendar days of the request.

This applies (for submission of case report forms) also to the time during the evaluation procedure unless a significant change of the SPC arises from single case reports.

3.1 Overview tables

Given the pivotal role of the overview tables for Parts III and IV, applicants are strongly urged to include these in submissions, as quickly as possible. In any event, consideration of a dossier in any of the Community procedures would be greatly facilitated by the presence of such overview tables.

A written summary, for the relevant sections of Part III and Part IV would facilitate mutual recognition by concerned Member States, and also consideration by the members of the Scientific Committee of the European Agency for the Evaluation of Medicinal Products.